PALO
ALTO, Calif., Nov. 8, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a
commercial-stage biopharmaceutical company focused on the
development of innovative therapies for hepatitis delta virus (HDV)
and other serious diseases, today announced that members of its
management team will participate in the following upcoming investor
conferences:
Stifel 2022 Healthcare Conference
- Date & Time: Tuesday, November 15,
2022 at 10:55 a.m. ET
- Format: Company presentation and one-on-one meetings
Jefferies London Healthcare Conference
- Date & Time: Wednesday, November 16,
2022 at 11:30 a.m. GMT
- Format: Company presentation and one-on-one meetings
A live webcast of each presentation will be available on the
Investors section of the Eiger BioPharmaceuticals website at
www.eigerbio.com. Replays will be available on the website for at
least 90 days.
About Eiger
Eiger is a commercial-stage
biopharmaceutical company focused on the development of innovative
therapies for hepatitis delta virus (HDV) and other serious
diseases. The Eiger HDV platform includes two first-in-class
therapies in Phase 3 that target critical host processes involved
in viral replication. All five Eiger rare disease programs have
been granted FDA Breakthrough Therapy designation: lonafarnib and
peginterferon lambda for HDV, Zokinvy for progeria, and avexitide
for both congenital hyperinsulinism and post-bariatric
hypoglycemia.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-investor-conferences-301672184.html
SOURCE Eiger BioPharmaceuticals, Inc.